Direct oral anticoagulant rivaroxaban for secondary prevention of catheter-related thrombosis in children with intestinal failure: real-life data
This is the first study to provide real-life insights into the use of the DOAC rivaroxaban in children with intestinal failure, demonstrating its potential for secondary CRT prevention and child-friendly administration with very low rethrombosis rate. However, dose adjustments based on therapeutic drug monitoring might be necessary due to heterogeneous variability in absorption. Future prospective and comparative trials are needed to confirm these findings.
Authors
- W. Eberl (ORCID: https://orcid.org/0000-0002-4559-0548)
- Antje Ballauff
- Johannes Nordmeyer (ORCID: https://orcid.org/0000-0001-6961-5773)
- Vanya Icheva (ORCID: https://orcid.org/0000-0001-8563-1466)
- Drieke Vermeulen
- Ekkehard Sturm (ORCID: https://orcid.org/0000-0002-1489-8662)
- Jörg Michel (ORCID: https://orcid.org/0000-0001-8376-4724)
- Justus Lieber (ORCID: https://orcid.org/0000-0003-1421-0984)
- Steffen Hartleif (ORCID: https://orcid.org/0000-0002-2608-5087)
- Johannes Hilberath (ORCID: https://orcid.org/0009-0005-0055-7452)
- Ludger Sieverding
- Aline Rückel
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Erlangen (DE)
- Helios Klinikum Krefeld (DE)
- Klinikum Braunschweig (DE)
- University Children's Hospital Tübingen (DE)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.rpth.2025.103231
- Citations
- 1
- Primary Topic
- Central Venous Catheters and Hemodialysis
- Type
- article
- Field-Weighted Citation Impact
- 2.52